Furthermore, multiple studies have already described various somatically-derived genomic 'signatures' in tumors that can predict both disease outcome and response to therapy, such as a 70 gene expression signature in breast tumors that can identify patients with particularly good prognoses [8], and EGFR mutations in lung cancers that can predict tumor response to EGFR-targeted therapies [9,10]. Here, EGFR is linked to lung carcinoma.